Additional file 1: Table S1. of Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study

Chest CT Parameters for Subjects With and Without History of Childhood Pneumonia. Table S2. Effect of Childhood Pneumonia with Childhood Asthmatics Removed. Table S3. Effect of Childhood Pneumonia in Childhood Asthmatics Only. Table S4. Recall Assessment in Subjects Who Did Not Report Known COPD or Emphysema Diagnosis. Figure S1. Classification of subjects in cohort based on childhood pneumonia status. Figure S2. Distribution of age of first pneumonia in entire cohort (a) in subjects with a history of childhood pneumonia (b) and in subjects without a history of childhood pneumonia (c). Includes all subjects who reported an age of first pneumonia. (PDF 943 kb

Lung and heart eNOS and iNOS mRNA.

<p>Mean ± SE, n = 6 animals per group. <b>A.</b> Lung eNOS: NS. <b>B.</b> Heart eNOS: NS. <b>C.</b> Lung iNOS: Two-way ANOVA. TIME x AEOL interaction, p < 0.001. Holm-Sidak: <b>a</b>, AEOL within 2 h: 0, 2 vs 5mg/kg, p < 0.001. <b>b</b>, AEOL within 24 h: 0 vs 5 mg/kg, p = 0.047. <b>D.</b> Heart iNOS: NS.</p

Plasma levels of isoprostane and 3-nitrotyrosine in animals treated with AEOL.

<p>Mean ± SE, n = 6 animals per group. <b>A</b>. Plasma isoprostane: Two-way ANOVA. AEOL main effect, p = 0.036. Holm-Sidak: <b>a</b>, 0 vs 2 mg/kg, p = 0.011. <b>B</b>. Plasma 3-nitrotyrosine: Two-way ANOVA. AEOL main effect, p = 0.003. Holm-Sidak: <b>b</b>, 0 vs 5 mg/kg, p < 0.001, and 2 vs 5 mg/kg, p < 0.040.</p

Lung and heart ET_A receptor and ET_B receptor mRNA.

<p>Mean ± SE, n = 6 animals per group. <b>A.</b> Lung ET_AR. Two-way ANOVA. AEOL main effect, p = 0.045. Holm-Sidak: <b>a</b> 0 vs 5 mg/kg, p = 0.014. <b>B.</b> Heart ET_A mRNA: NS. <b>C.</b> Lung ET_BR: Two-way ANOVA. TIME main effect, p = 0.028. Holm-Sidak: <b>b</b>, 2 vs 24 h, p < 0.05. <b>D.</b> Heart ET_B mRNA: NS.</p

Plasma levels of bigET-1, ET-1, ET-2 and ET-3 peptides in animals treated with AEOL.

<p>Mean ± SE, n = 6 animals per group. <b>A.</b> BigET-1: NS. <b>B.</b> ET-1: Two-way ANOVA. TIME main effect, p = 0.042. Holm-Sidak: <b>a</b>, 2 h vs 24 h, p < 0.05. AEOL main effect, p = 0.001. Holm-Sidak: <b>b</b>, 0, 2 vs 5 mg/kg, p < 0.001. <b>C.</b> ET-2: NS. <b>D.</b> ET-3: Two-way ANOVA. AEOL main effect, p = 0.014. Holm-Sidak: <b>c</b>, 2 vs 5 mg/kg, p = 0.004.</p

Additional file 1 of Pectoralis muscle area and mortality in smokers without airflow obstruction

Figure S1. Plot of the pectoralis muscle area (PMA) to paravertebral muscle area (PVMA). The relationship between the muscle groups was significant (R2 = 0.44, P < 0.0001). Table S1 Baseline characteristics of at-risk smokers by quartile of PVMA (N = 3705). (DOCX 207 kb

Additional file 2: of The value of blood cytokines and chemokines in assessing COPD

Cross Sectional Associations by Subgroup Heat Map. (PDF 156 kb

Additional file 1: Table S1. of Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study

IRB Approval and Protocol Numbers for COPDGene. (DOCX 26 kb

Characteristics of participants with COPD based upon number of comorbidities.

<p>All values as mean(SD) unless otherwise indicated.</p><p>Characteristics of participants with COPD based upon number of comorbidities.</p

Discrimination measures (AUC) and calibration measures (Hosmer-Lemeshow calibration statistics) for comorbidity count with regards to outcomes of exacerbations, MMRC, and 6MWD, in the SPIROMICS participants.

<p>Above models also include terms for age, gender, race, baseline FEV1, pack-years smoked and current smoking status. Every score above added to “empty” model, with addition of score improving AUC significantly (p<0·001 for all comparisons). The AUCs for the empty models are as follows: SGRQ 0.7741, Exacerbations 0.7223, MMRC 0.7499, 6MWD 0.6970. For associations with outcome, OR for exacerbations represents risk for exacerbation conferred by one point increase in comorbidity score, OR for MMRC represents risk for worse dyspnea score conferred by one point increase in comorbidity score, and β's for SGRQ and 6MWD represent decrement in health status and exercise capacity conferred by one point increase in comorbidity score. All ROCs estimated using logistic regression with outcomes of SGRQ (group mean 35.4, SD 18.9), MMRC (group mean 1.18, SD 0.99) and 6MWD (group mean 395.5, SD 112.5) dichotomized at group mean.</p><p>Discrimination measures (AUC) and calibration measures (Hosmer-Lemeshow calibration statistics) for comorbidity count with regards to outcomes of exacerbations, MMRC, and 6MWD, in the SPIROMICS participants.</p